The chelating agent 2,3 dimercaptopropane-1-sulfonate (DMPS) has been used in a mercury mobilization test for diagnoses in illnesses allegedly associated with the presence of amalgam restorations. DMPS is an accepted antidote to heavy metal poisoning. The aim of the present study was to evaluate the diagnostic value of DMPS in patients with symptoms self-related to their amalgam fillings. The subjects consisted of four groups: 19 healthy controls without amalgam experience; 21 healthy controls with amalgam fillings; 20 patients who claimed symptoms of "mercury poisoning" from dental amalgam; and 20 patients who had amalgam fillings removed because of such symptoms. DMPS (2 mg/kg body weight) was injected intravenously, and urine was collected prior to the injection, 30 and 120 min after the injection, and throughout the next 22 hrs. The samples were analyzed for total mercury by cold vapor atomic absorption spectrophotometry. The total median amounts of mercury excreted over 24 hrs for those with complaints allegedly associated with amalgam and for the healthy controls with amalgam fillings were similar. Persons with amalgam fillings excreted about three times more mercury than those without. The controls, who had never had amalgam fillings, and the subjects who had had their fillings removed excreted median amounts of 8.5 μg and 7.2 μg mercury, respectively. The present DMPS challenge test did not differentiate between patients with or those without complaints self-related to their amalgam fillings but did confirm the higher mercury values in patients with dental amalgam.
Aaseth J., Jacobsen D., Andersen 0, Wickstrom E. (1995). Treatment of mercury and lead poisonings with dimercaptosuccinic acid and sodium dimercaptopropanesulfonate. A review. Analyst120:853-854.
2.
Ahlqwist M., Bengtsson C., Lapidus L., Lindstedt G., Lissner L. (1995). Concentrations of blood, serum and urine components in relation to number of amalgam tooth fillings in Swedish women. Community Dent Oral Epidemiol23:217-221.
3.
Aposhian HV, Maiorino RM, Gonzalez Ramirez D., Zuniga-Charles M., Xu Z., Hurlbut KM, et al. (1995). Mobilization of heavy metals by newer, therapeutically useful chelating agents. Toxicology97:23-38.
4.
Aposhian MM, Maiorino RM, Xu Z., Aposhian HV (1996). Sodium 2,3-dimercapto-l-propanesulfonate (DMPS) treatment does not redistribute lead or mercury to the brain of rat. Toxicology109:49-55.
5.
Barber TE, Wallis G. (1986). Correction of urinary mercury concentration by specific gravity, osmolality, and creatinine. J Occup Med28:354-359.
6.
Benson JS, Alavanja Mcr, Carnevale CW, Coene RF, Flynn BW, Hardin BD, et al. (1993). Dental amalgam: a scientific review and recommended public health service strategy for research, education and regulation. Final report of the Subcommittee on Risk Management of the Committee to Coordinate Environmental Health and Related Programs, Public Health Service. Washington, DC: Department of Health & Human Services.
7.
Berglund A. (1990). Estimation by a 24-hour study of the daily dose of intra-oral mercury vapor inhaled after release from dental amalgam. J Dent Res69:1646-1651.
8.
Berglund A., Molin M. (1996). Mercury vapor release from dental amalgam in patients with symptoms allegedly caused by amalgam fillings. Eur J Oral Sci104:56-63.
9.
Berglund A.Pohl L., Olsson S., Bergman M. (1988). Determination of the rate of release of intra-oral mercury vapor from amalgam. J Dent Res67:1235-1242.
10.
Berlin M. (1986). Mercury. In: Handbook on the toxicology of metals. 2nd ed. Friberg L, Nordberg GF, Voulk V, editors. Amsterdam: Elsevier Science Publishers, pp. 387-445.
11.
Bratel J., Haraldson T., Ottosson JO (1997). Potential side effects of dental amalgam restorations. (II) No relation between mercury levels in the body and mental disorders. Eur J Oral Sci105 :244-250.
12.
Cherian MG, Miles EF, Clarkson TW, Cox C. (1988). Estimation of mercury burdens in rats by chelation with dimercaptopropane sulfonate. J Pharmacol Exp Ther245:479-484.
13.
Daunderer M. (1989). Quecksilbervergiftungen durch Amalgam. Leitsymptom: Kopfschmerzen. Forum Prakt Allgemeinartz28 :89-91.
14.
Eide R., Wesenberg GR (1993). Mercury contents of indicators and target organs in rats after long-term, low-level, mercury vapor exposure. Environ Res61:212-222.
15.
Ewan KB, Pamphlett R. (1996). Increased inorganic mercury in spinal motor neurons following chelating agents. Neurotoxicology17 :343-349.
16.
Fawer RFde Ribaupierre Y., Guillemin MP, Berode M., Lob M. (1983). Measurement of hand tremor induced by industrial exposure to metallic mercury. Br J Ind Med40:204-208.
17.
Godfrey M., Campbell N. (1994). Confirmation of mercury retention and toxicity using 2,3-dimercapto-1-propane-sulphonic acid sodium salt (DMPS). J Adv Med7:19-30.
18.
Hanson M., Pleva J. (1991). The dental amalgam issue. A review. Experientia47:9-22.
19.
Herrmann M., Schweinsberg F. (1993). Biomonitoring zur Beurteilung einer Quecksilberbelastung aus Amalgamfullungen. Quecksilberbestimmung in Urin vor und nach oraler Gabe von 2,3-Dimaercapto-1-Propansulfonsaure (DMPS) und in Haaren. Zentralbl Hyg Umweltmed194:271-291.
20.
Hurlbut KM, Maiorino RM, Mayersohn M., Dart RC, Bruce DC, Aposhian HV (1994). Determination and metabolism of dithiol chelating agents. XVI: Pharmacokinetics of 2,3-dimercapto-1-propanesulfonate after intravenous administration to human volunteers. J Pharmacol Exp Ther268:662-668.
21.
Kroncke A., Ott K., Petschelt A., Schaller KH, Szecsi M., Valentin H. (1980). Über die Quecksilberkonzentrationen in Blut und Urin von Personen mit und ohne Amalgamfullungen. Dtsch Zahnärztl Z35:803-808.
22.
Langworth S., Elinder CG, Akesson A. (1988). Mercury exposure from dental fillings. I. Mercury concentrations in blood and urine. Swed Dent J12:69-70.
23.
Langworth S., Elinder CG, Sundqvist KG (1993). Minor effects of low exposure to inorganic mercury on the human immune system. Scand J Work Environ Health19:405-413.
24.
Lorscheider FL, Vimy MJ ( 1993). Evaluation of the safety issue of mercury release from dental fillings. FASEB J7:1432-1433.
25.
Mackert JR Jr, Berglund A. (1997). Mercury exposure from dental amalgam fillings: absorbed dose and the potential for adverse health effects. Crit Rev Oral Biol Med8:410-436.
26.
Maiorino RM, Aposhian HV (1989). Determination and metabolism of dithiol chelating agents. IV. Urinary excretion of meso-2,3-dimercaptosuccinic acid and mercaptosuccinic acid in rabbits given meso-2,3-dimercaptosuccinic acid. Biochem Pharmacol38:1147-1154.
27.
Maiorino RM, Dart RC, Carter DE, Aposhian HV (1991). Determination and metabolism of dithiol chelating agents. XII. Metabolism and pharmacokinetics of sodium 2,3-dimercaptopropane-1-sulfonate in humans. J Pharmacol Exp Ther259:808-814.
28.
Nylander M., Friberg L., Lind B. ( 1987). Mercury concentrations in the human brain and kidneys in relation to exposure from dental amalgam fillings. Swed Dent J11:179-187.
29.
Olsson S., Bergman M. (1992). Daily dose calculations from measurements of intra-oral mercury vapor. J Dent Res71:414-423.
30.
Olstad ML, Holland RI, Wandel N., Hensten-Pettersen A. (1987). Correlation between amalgam restorations and mercury concentrations in urine. J Dent Res66:1179-1182.
31.
Oskarsson A., Schutz A., Skerfving S., Hallen IP, Ohlin B., Lagerkvist BJ (1996). Total and inorganic mercury in breast milk in relation to fish consumption and amalgam in lactating women. Arch Environ Health51:234-241.
32.
Oster 0, Prellwitz W. (1985). Die Pathobiochemie, Diagnose und Therapie der Metall- und Metalliodinintoxication. Teil 2: Die Quecksilberintoxikation. Intensivmedizin22:130-139.
33.
Petrunkin VE (1956). Synthesis and properties of dimercapto derivates of alkylsulfonic acids. 1: Synthesis of sodium 2,3-dimercaptopropylsulfonate (unithiol) and sodium 2-mercaptoethylsulfonate. Ukr Khim Zh22:603-607.
34.
Roels H., Gennart JP, Lauwerys R., Buchet JP, Malchaire J., Bernard A. (1985). Surveillance of workers exposed to mercury vapour: validation of a previously proposed biological threshold limit value for mercury concentration in urine. Am J Ind Med7:45-71.
35.
Ruprecht J. (1993). DMPS mobilization test. In: DMPS-Heyl. Summary of scientific literature. Berlin, Germany: Heyl.
36.
Sallsten G., Thoren J., Barregard L., Schutz A., Skarping G. (1996). Long-term use of nicotine chewing gum and mercury exposure from dental amalgam fillings. J Dent Res75:594-598.
37.
Sandborgh-Englund G., Elinder C-G., Langworth S., Schutz A., Ekstrand J. (1998). Mercury in biological fluids after amalgam removal . J Dent Res77:615-624.
38.
Schiele R., Kroncke A. (1989). Mercury mobility through DMPS (Dimaval) in persons with and without amalgam fillings. Zahnärztl Mitt79:1866-1868.
39.
Schiele R., Schaller KH, Welte D. (1989). Mobilisation von Quecksilber-Speicherungen im Organismus mittels DMPS (Dimaval). Arbeitsmed Sozialmed Praventivmed24:249-251.
40.
Siblerud RL, Kienholz E. (1994). Evidence that mercury from silver dental fillings may be an etiological factor in multiple sclerosis. Sci Total Environ142:191-205.
41.
Socialstyrelsen (1994). Blir man sjuk av amalgam? SoS-rapport. Socialstyrelsen. Stockholm. Sweden 1994:21. ISBN 91-38-11407-0. ISSN 100-2808.
42.
Stenman S., Grans L. (1997). Symptoms and differential diagnosis of patients fearing mercury toxicity from amalgam fillings. Scand J Work Environ Health23:59-63.
43.
Summers AO, Wireman J., Vimy MJ, Lorscheider FL, Marshall B., Levy SB, et al. (1993). Mercury released from dental "silver" fillings provokes an increase in mercury- and antibiotic-resistant bacteria in oral and intestinal floras of primates. Antimicrob Agents Chemother37:825-834.
44.
Vimy MJ, Lorscheider FL (1985). Intra-oral air mercury released from dental amalgam . J Dent Res64:1069-1071.
45.
Waelti S. (1992). Pharmakokinetik der uroprotektiven Sulfhydrylgruppen in Urin gesunder Probanden nach peroraler Verabreichung von Na-mercaptoethansulfonat (Uromexitan) und von Na-Dimercaptopropansulfonat (Dimaval) (dissertation) . Bern, Switzerland: Universitat Bern.
46.
Weiner JA, Nylander M. (1993). The relationship between mercury concentration in human organs and different predictor variables. Sci Total Environ138:101-115.
47.
Wildenauer DB, Reuther H., Weger N. (1982). Interaction of the chelating agent 2,3-dimercaptopropane-l-sulfonate with red blood cells in vitro. I. Evidence for carrier mediated transport . Chem Biol Interact42:165-177.
